Fig. 1From: Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in ChinaThe structure of the partitioned survival modelBack to article page
